Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

104.04 -1.02 (-0.97%)
Streaming Delayed Price Updated: 12:24 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
65 66 Next >
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Profit from corporate cash splurges with these top ETFs targeting buyback strategies. Unlock potential gains in a volatile market. 
Via InvestorPlace
Topics ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
3 Pharma Stocks That Are Money-Printing Machines in 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
Exposures Economy
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
Via Benzinga
Check Out What Whales Are Doing With NVO
Via Benzinga
Is NYSE:NVO a Good Fit for Dividend Investing?
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a good dividend investing stock. 
Via Chartmill
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
The collaboration could help solve challenges for both businesses. 
Via The Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders 
Via MarketBeat
NYSE:NVO is showing good growth, while it is not too expensive.
For those who appreciate growth without the sticker shock, NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is worth considering. 
Via Chartmill
Viking Therapeutics: Strong Results In Obesity
With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100... 
Via Talk Markets
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
AI leader Nvidia bucked the S&P 500 downdraft last week. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... 
Via Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
U.S. District Judge Roy Altman's ruling prohibits Eli Lilly from using state law to halt RXCompoundStore.com's marketing of its tirzepatide version. The court asserts federal law enforcement authority,... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee found no conclusive evidence linking GLP-1 receptor agonists to suicidal or self-injurious thoughts. Following thorough... 
Via Benzinga
Exposures Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end? 
Via Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades. 
Via InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now. 
Via InvestorPlace
What's Going On With Ginkgo Bioworks Stock?
Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agreement that initially is contemplated to run over five years.Ginkgo said the... 
Via Benzinga
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak. 
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments 
Via InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in April
Don't wait too long to invest in these exciting stocks. 
Via The Motley Fool
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
It may not be too late to invest in this promising healthcare stock, even though it may look expensive. 
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend 
Via MarketBeat
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Shares of the clinical-stage biotech have skyrocketed on recent good news. 
Via The Motley Fool
Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?
New findings could lead to more growth from their prized medicines. 
Via The Motley Fool
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.